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Introduction: Carnitine is an essential cofactor in mitochondrial fatty acid oxidation. Carnitine deficiency results in
accumulation of non-oxidized fatty acyl-coenzyme A molecules, and this inhibits intra-mitochondrial degradation of
ammonia. Hyperammonemia may lead to encephalopathy. This scenario has been previously reported.
Case presentation: We report the case of a 47-year-old Caucasian man who had sustained a remote motor vehicle
accident injury and relied on long-term tube feeding with a commercial product that wascarnitine-free. He was also
on phenytoin therapy for control of his chronic seizures. He developed significant acute psychological and
behavioral changes superimposed on his chronic neurological impairment. His ammonia level was found to be
elevated at 75 to 100μmol/L (normal <35μmol/L). Phenytoin was found to be at a supra-therapeutic level of
143μmol/L (therapeutic range 40–80μmol/L). After adjusting the dose of phenytoin, other pharmacological and
hepatic causes of his hyperammonemia and subacute encephalopathy were excluded. His carnitine levels were
found to be low. After initiating carnitine supplementation at 500mg twice daily, the patient’s mental status
improved, and his ammonia level improved to 53–60μmol/L.
Conclusion: This case illustrates the importance of avoiding carnitine deficiency and anti-convulsant toxicity in
tube-fed patients encountered in hospital wards and nursing homes. These patients should have their carnitine
levels assessed regularly, and supplementation should be provided as necessary. Manufacturers of enteral feeds and
formulas should consider adding carnitine to their product lines.Introduction
Carnitine is an essential cofactor synthesized in liver and
kidney cells from lysine and methionine. It allows oxida-
tion of long-chain fatty acids [1]. This process is import-
ant because unoxidized fatty acid can accumulate and
inhibit the urea cycle, resulting in hyperammonemia [1].
Carnitine can also be obtained from dietary sources, with
the highest concentrations of carnitine found in red meat
and dairy products [2]. Primary carnitine deficiency may
result from hereditary defects in the carnitine transport* Correspondence: Sandra.Sirrs@vch.ca
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reproduction in any medium, provided the orsystem. Presentations can range from being completely
asymptomatic all the way to severe neonatal encephal-
opathy [3]. In contrast, secondary or acquired carnitine
deficiency occurs in adults, especially in those with cir-
rhotic liver disease and those who receive long-term
total parenteral nutrition (TPN) with insufficient carni-
tine supplementation [3]. Major clinical presentations of
carnitine deficiency are hyperammonemic encephalop-
athy, hypoketotic hypoglycemia, and cardiomyopathy [1].
We present the case of a patient who has been on long-
term percutaneous endoscopic gastrostomy (PEG) tube
feeding with a carnitine-free feed, manifesting as hyper-
ammonemic encephalopathy. Carnitine deficiency is a
rare entity which is frequently not recognized, and this
case report demonstrates the importance of awareness of
acquired carnitine deficiency in patients receiving TPN.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Our patient was a 47-year-old Caucasian man with a re-
mote history of head injury and long-term PEG feeding
in a nursing home who had developed increasing agita-
tion and confusion. The patient had a closed head injury
from a motor vehicle accident sustained 23 years previ-
ously. Since then he has had chronic but stable cognitive
impairment and resides in an extended care facility. At
baseline, he was able to talk and make simple decisions,
but not complex ones such as those regarding his care.
He is totally unable to perform his activities of daily liv-
ing (ADLs) and is transferred using a ceiling lift and a
two-person assist. He required tracheostomy for breath-
ing and was fed via a PEG tube with IsosourceW HN for-
mula (Nestlé Nutrition™, Highland Park, MI, USA)
without carnitine (Table 1). He had been stable on tube
feeds for many years. His calculated body mass index
(BMI) was 24kg/m2, and his caloric intake via enteral
feeds was 1800kcal/day. His other medical problems
included a chronic foot ulcer without active infection
and diabetes mellitus. He did not have any history of
rhabdomyolysis, cardiac disease, liver disease, or renal
insufficiency that would have suggested an underlying
genetic defect in fatty acid oxidation. An unexplained
acute change in his cognitive and/or psychological func-
tion and behavior occurred when he became increasingly
confused and drowsy. As the patient had been on chronic
phenytoin therapy for years, his phenytoin level was
checked and found to be above the therapeutic range at
143μmol/L (therapeutic range 40 to 80μmol/L). His
phenytoin dose was adjusted such that, days later, the
level was 63μmol/L. Despite the achievement of thera-
peutic phenytoin concentration, his cognitive changes
did not return to baseline. He continued to be delirious
with a reversed sleep cycle. The phenytoin was further
adjusted such that the level was subtherapeutic at
14μmol/L without improvement in his cognitive status.
He did not return to his baseline level of function, being
oriented only to person and unable to answer questions.
We evaluated him for other causes of confusion, which
showed that his hematological profile, electrolytes, and
renal function were normal. The glucometer reading was
6.6mmol/L at the time when he was first assessed for
his confusion (hemoglobin A1C unknown). His liver bio-
chemistry and International Normalized Ratio remained
normal, and the serum total bilirubin was 8μmol/L
(normal <18μmol/L ). The serum albumin level was low
(29g/L) without any manifestation of hypoalbuminemia.
Evidence of myopathy was difficult to assess clinically,
given the neurologic compromise due to his remote
accident. Creatine kinase and myoglobinuria were not
measured at the time. His serum ammonia level, how-
ever, was high on multiple measurements taken under
ideal conditions, ranging from 75 to 100μmol/L (normal<35μmol/L). The patient was not on any medication as-
sociated with hyperammonemia. His enteral feed, Iso-
sourceW HN, did not contain supplemental carnitine, and
his serum carnitine and plasma amino acid concen-
trations were measured. His total carnitine was low at
20.5μmol/L (normal 30 to 63μmol/L), and his free carni-
tine was 17.2μmol/L (normal 22 to 59μmol/L). Acyl car-
nitine levels in urine were measured before and after
carnitine supplementation, and they did not show find-
ings suggestive of an underlying genetic defect of fatty
acid oxidation. Plasma concentrations of ornithine (71μM),
citrulline (34μM), and arginine (68μM) were normal, so
there was no evidence of an undiagnosed urea cycle
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carnitine 500mg twice daily via his PEG tube was
initiated. His diet was otherwise the same without pro-
tein being removed from the diet. The patient’s confusion
subsequently improved, and he was restored to his base-
line neurological state, free of confusion, agitation, or be-
havioral disturbances within 1 month of the carnitine
supplementation. Repeat serum ammonia concentration
after carnitine supplementation decreased promptly to
53 to 60μmol/L.
Discussion
Conditions associated with hyperammonemic encephal-
opathy includes organic acidemias, fatty acid oxidation
defects, pyruvate metabolism disorders, liver failure, urea
cycle defects, and Reye’s syndrome. Iatrogenic causes
include adverse drug effects (e.g. valproic acid), TPN
with carnitine-free feeds, and transjugular intra-hepatic
portosystemic shunts (TIPS) [4]. Rarer causes of hyper-
ammonemia include hyperornithinemia and homoci-
trullinemia, which are both associated with urea cycle
defects [5]. This patient had neither liver disease nor
aspirin use associated with Reye’s syndrome. Other than
phenytoin, he was not on any medications associated
with hyperammonemia. His normal amino acid profile
excluded intrinsic urea cycle defect or undiagnosed ami-
noacidopathy. Given the long term use of carnitine-
free feeds, carnitine deficiency is considered in this case.
The patient had been clinically stable without hyperam-
monemia on the same feeding regimen for years. There-
fore, the improvement in his encephalopathy was a
consequence of carnitine supplementation, instead of
secondary to changes in protein content in his diet.
In humans, approximately 75% of body carnitine
comes from the diet, such as from meat, fish, and dairy
products, and 25% comes from de novo biosynthesis
from lysine, methionine, and other cofactors [6]. Skeletal
and cardiac muscle tissues are the main storage sites for
carnitine. Our patient had been on long-term carnitine-
free feeds. Repleting all other nutrients without carnitine
further raised the tissue requirement for carnitine. In
addition, the patient had a low carnitine reserve from
his decreased skeletal muscle mass secondary to his
physical disability, as evidenced by his creatinine level of
43μmol/L. Endogenous synthesis of carnitine is reduced
by undernutrition for iron, protein, niacin, and vitamins
C and B6, all of which are building blocks for carnitine
[2]. Feller et al. described 19 nursing home patients who
were chronically tube-fed with protein hydrolysate for-
mulae. In half of these individuals, low total and free
carnitine levels were detected [2]. These data suggest
that elderly patients who are on carnitine-free diets may
not have sufficient endogenous synthesis to maintain a
normal carnitine level.One case report [7] described an adult man who, after
1 year of TPN, developed hyperbilirubinemia, hypo-
glycemia, and generalized muscle weakness. His plasma
carnitine was found to be low. Intravenous supplementa-
tion with carnitine corrected the plasma carnitine defi-
ciency, hyperbilirubinemia, and hypoglycemia, and it
restored the skeletal muscle strength. That patient was
also found to have a supratherapeutic level of phenytoin
at the time of hyperammonemic encephalopathy [7].
Anti-convulsants such as phenytoin and valproate were
reported to lower serum carnitine concentrations [8-10].
Phenytoin, to a lesser extent than valproate, can interfere
with tubular reabsorption of carnitine in the kidney [2].
Despite normalization of phenytoin to a therapeutic level,
our patient’s cognitive changes did not return to his base-
line, and his serum carnitine level was still low. In an
otherwise healthy patient, the supratherapeutic range of
phenytoin probably does not result in clinical manifest-
ation of carnitine deficiency. In a case such as that of our
patient, however, who was already hypocarnitinemic
from his feeds, phenytoin toxicity can turn a borderline
situation into one that is clinically relevant. His prompt
clinical improvement due to carnitine supplementation
illustrates his marked carnitine deficiency.
Conclusions
In healthy adults, carnitine is dispensable because of ad-
equate endogenous synthetic ability. In patients with im-
paired carnitine synthetic capacity and exposure to low
carnitine diets, however, such as the debilitated patients
with chronic tube-feeding and chronic use of anti-con-
vulsants, carnitine deficiency is a condition that physi-
cians should keep in mind. In the absence of other
causes of hyperammonemia, carnitine deficiency should
be considered in the differential diagnosis. These patients
should have carnitine levels regularly assessed, and sup-
plementation should be provided as necessary. Manufac-
turers of enteral feeds and formula should also consider
adding carnitine to their products.
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